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Background: In a previous report, we compared the conformity of robust intensity-modulated proton therapy
(IMPT) plans with that of helical tomotherapy plans for re-irradiations of head and neck carcinomas using a fixed
set-up error of 2 mm. Here, we varied the maximum set-up errors between 0 and 5 mm and compared the robust
IMPT-plans with planning target volume (PTV) based intensity-modulated photon therapy (IMRT).
Findings: Seven patients were treated with a PTV-based tomotherapy plan. Set-up margins of 0, 2, and 5 mm were
subtracted from the PTV to generate target volumes (TV) TV0mm, TV2mm, and TV5mm, for which robust IMPT-plans
were created assuming range uncertainties of ±3.5% and using worst case optimization assuming set-up errors of 0,
2, and 5 mm, respectively. Robust optimization makes use of the feature that set-up errors in beam direction alone
do not affect the distal and proximal margin for that beam. With increasing set-up errors, the body volumes that
were exposed to a selected minimum dose level between 20% and 95% of the prescribed dose decreased. In IMPT-
plans with 0 mm set-up error, the exposed body volumes were on average 6.2% ± 0.9% larger than for
IMPT-plans with 2 mm set-up error, independent of the considered dose level (p < 0.0001, F-test). In IMPT-plans
accounting for 5 mm set-up error, the exposed body volumes were by 11.9% ± 0.8% smaller than for IMPT-plans
with 2 mm set-up error at a fixed minimum dose (p < 0.0001, F-test). This set-up error dependence of the normal
tissue exposure around the TV in robust IMPT-plans corresponding to the same IMRT-plan led to a decrease in the
mean dose to the temporal lobes and the cerebellum, and in the D2% of the brain stem or spinal cord with
increasing set-up errors considered during robust IMPT-planning.
Conclusions: For recurrent head and neck cancer, robust IMPT-plan optimization led to a decrease in normal tissue
exposure with increasing set-up error for target volumes corresponding to the same PTV.
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The consideration of a 2 mm set-up error seems ad-
equate for small targets in the head and neck region
when daily online navigation is used [1,2]. However, in
the head and neck region, less frequent online correction
protocols and off-line protocols correcting only system-
atic set-up errors may require margins between the clin-
ical target volume (CTV) and the planning target
volume (PTV) accounting for larger set-up errors of
5 mm or more [3,4].
Robust intensity-modulated proton therapy (IMPT)
treatment plan optimization, optimizing the dose distri-
bution in the worst case of multiple scenarios covering
possible realizations of set-up errors and density varia-
tions, can result in treatment plans that maintain target
volume coverage and normal tissue sparing in the pres-
ence of set-up errors and range uncertainties [5-10]. A
single scenario PTV based treatment planning may not
be sufficient for IMPT because possible spatial devia-
tions of dose gradients between spots can affect dose
homogeneity within the PTV with set-up error [5,11].
In a previous study, we compared dose conformity and
normal tissue exposure of intensity-modulated photon
plans for helical tomotherapy with robust IMPT-plans
for set-up errors of 2 mm [6]. Here, we test the per-
formance of the robust multi-scenario based IMPT
optimization to spare normal tissues around a given
PTV per patient for different set-up errors varying be-
tween 0 and 5 mm. With increasing set-up errors, the
CTV-PTV set-up margin contains an increasing portion
of the PTV and robust IMPT optimization based on
the CTV may lead to results which depend systematic-




The analysis was based on 7 patients with recurrent
head and neck carcinomas who were re-irradiated
using helical tomotherapy. Patients and tomotherapy
treatment planning were described in a previous publi-
cation [6].
Intensity-modulated proton therapy planning
Target volumes TV0mm, TV2mm, and TV5mm were
obtained from the original tomotherapy PTV of each pa-
tient by concentric shrinkage by 0, 2, and 5 mm, respect-
ively. IMPT-plans were generated to cover TV0mm,
TV2mm, and TV5mm using the field configurations de-
scribed in the previous study [6]. Robust optimization
was used assuming a range, i.e. density, uncertainty of
+/− 3.5%. In addition, maximum set-up errors of 0, 2,
and 5 mm in each direction were considered in the ro-
bust optimization of the IMPT-plans based on TV0mm,TV2mm, and TV5mm, respectively. IMPT planning was
performed using the RayStation v2.4.13.31 planning sys-
tem as described by Fredrikson et al. [7]. Robust
optimization evaluates the penalties of the original plan
and the plans with shifted beam isocenters correspond-
ing to the maximum set-up errors and altered density
scalings. Optimization of the pencil beam spot weights is
performed to minimize the penalties of the worst case
scenario. In a previous publication, IMPT-plans assum-
ing set-up errors of 2 mm and using TV2mm as CTV
were compared to tomotherapy plans optimized on the
PTV, i.e. TV0mm [6]. In the present study, we compared,
for every patient, the robust IMPT-plans based on
TV0mm, TV2mm, and TV5mm, assuming maximum set-up
errors of 0, 2, and 5 mm, respectively (IMPT0mm,
IMPT2mm, and IMPT5mm, respectively) with the original
PTV-based tomotherapy photon plan. Differences in the
dose distributions of the IMPT0mm-, IMPT2mm-, and
IMPT5mm-plans reflect the performance of a robust
scenario-based optimization to handle set-up errors in
comparison to a PTV-based approach.
Statistical analysis
The effect of the set-up error on the body volume ex-
posed to doses higher than x% of the prescribed dose
(Vbodyx%), where 20% ≤ x% ≤ 95%, in the IMPT-plans
IMPT0mm, IMPT2mm, and IMPT5mm, respectively, was
analyzed using Proc Glm, SAS statistical software Ver-
sion 9.2 (Cary, NC). The logarithm of the ratio of Vbodyx
% exposed in plan IMPTymm to Vbodyx% exposed in plan
IMPT2mm (i.e. Log(Vbodyx% in IMPTymm / Vbodyx% in
IMPT2mm) was used as dependent variable, where ymm
denotes a set-up error of y mm. The set-up error was
used as an independent classification variable, the indi-
vidual patient as a random variable, and the dose level x
and the square of the dose level x∙x as continuous re-
gressor variables. Dose differences to organs at risk in
the IMPTymm-plans compared with the IMPT2mm-plans
were analyzed in a similar manner.
Results
Exposed body volumes
For all evaluated isodose levels x between 20% and 95%,
Vbodyx% exposed in the robust 5 mm plans (IMPT5mm)
was on average smaller (mean: -11.9%, 95% confidence
interval of the mean: -13.4% to −10.3%, p < 0.0001, F-test)
than Vbodyx% exposed in the robust 2 mm plans
(IMPT2mm). Compared with the IMPT2mm-plans, a 6.2%
increase of the exposed body volume Vbodyx% was
obtained in the 0 mm plans (IMPT0mm), averaged over all
patients and isodose levels (95% confidence interval: 4.4%
to 8.1%, p < 0.0001, F-test). The deviations of the body vol-
umes exposed in the IMPT5mm- and IMPT0mm-plans from
the body volume exposed in the IMPT2mm-plan did not
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linear nor a quadratic term of x became significant using a
Taylor series expansion (p > 0.25 for each term). Figure 1
shows the ratios of Vbodyx% exposed in the IMPT5mm-
and IMPT0mm-plans over Vbodyx% exposed in the
IMPT2mm-plan for all 7 patients and all evaluated isodose
levels x between 20% and 95%. There was a significant
inter-patient variability in the mean increase of the exposed
body volume for the IMPT0mm-plans compared with the
IMPT2mm-plans over Vbodyx% (p < 0.0001, F-Test). The
smallest increase amounted to 1.2% (patient 6), the largest
increase was 19.0% (patient 1) (mean increase: +6.2%). The
inter-patient variability in the decrease of the exposed body
volume for the IMPT5mm-plans compared with the
IMPT2mm-plans was also significant (p < 0.0001, F-Test).
The smallest decrease was −6.9% (patient 6), the largest
decrease amounted to −18.6% (patient 1) (mean
decrease: -11.9%). Average depths of the proximal and
distal CTV border at the isocenter were 3.7 cm and
8.6 cm, respectively, over all coplanar fields for the
considered patients with larger inter-field variations.
The corresponding range uncertainties were 1.3 mm
and 3.0 mm in this study.
Figure 2 shows dose difference plots calculated by
subtracting the dose distribution of the IMPT2mm-plan
from the dose distribution of the IMPT0mm- andFigure 1 Exposed body volumes. Body volumes exposed to doses
higher than x% of the prescribed dose (Vbodyx%) in robust
IMPT-plans assuming set-up errors of 0, 2, and 5 mm around the
target volume derived from the original PTV through isotropic
shrinkage by set-up margins of 0, 2, and 5 mm, respectively, for 7
patients with recurrent head and neck carcinomas and evaluated
isodose levels x between 20% and 95%. The ratios of Vbodyx% in the
0 and 5 mm IMPT-plans (IMPT5mm and IMPT0mm, respectively) over
Vbodyx% exposed in the 2 mm IMPT-plan (IMPT2mm) are displayed by
red circles and green triangles, respectively. A significant decrease
of −11.9 ± 0.8% in Vbodyx% in the robust IMPT5mm-plan was obtained
in comparison with Vbodyx% exposed in the robust IMPT2mm-plan
(p < 0.0001, F-Test). The respective increase in Vbodyx% in the
IMPT0mm-plan was 6.2 ± 0.9% (p < 0.0001, F-Test).IMPT5mm-plans for patients 1 and 7, respectively. These
dose difference distributions demonstrate the increase of
the dose around the target volume in the 0 mm IMPT-
plan and the decrease of the dose in the 5 mm IMPT-
plan compared with the 2 mm IMPT-plan. On average,
the TV0mm-size was 20% larger and the TV5mm-size 37%
smaller than the size of the TV2mm. The absolute values
are given in [6].
The coverage of the robust IMPT-plans for 0, 2, and
5 mm set-up errors remained high with respect to the
relevant target volumes TV0mm, TV2mm, and TV5mm. In
the IMPT0mm-plans, the dose to 95% of the target vol-
ume was >98% of the prescribed dose for patients 1 and
6 and >100% of the prescribed dose for all other pa-
tients. In the IMPT2mm- and IMPT5mm-plans, the dose
to 95% of the target volume was >95% of the prescribed
dose for patient 1 and >100% for all other patients. The
robustness against diagonal set-up errors was tested for
the 2 and 5 mm IMPT-plans by shifting the plan
isocenter by 1.5 or 3.5 mm in the lateral and ventro-
dorsal directions and applying a density change of +3%.
The IMPT5mm-plans were as robust against combined
set-up errors of 3.5 mm in the directions specified above
as the IMPT2mm-plan against set-up errors of 1.5 mm.
Normal tissue exposure
Dose difference distributions between the IMPT0mm-
and the IMPT2mm-plans and between the IMPT5mm-
and the IMPT2mm-plans were also analyzed with respect
to the exposure of selected normal tissues and organs at
risk. Differences in the mean doses to the ipsilateral
temporal lobe and to the cerebellum in the IMPT0mm-
and IMPT5mm-plans compared with the IMPT2mm-plan
are shown in Figure 3 for the 7 patients. The mean doses
to the ipsilateral temporal lobe and to the cerebellum
showed a dependence on the size of the set-up error
considered in the robust optimization (p = 0.009 and p =
0.001, F-tests). Smaller mean doses were obtained for
larger set-up errors considered. The same holds for the
D2%-differences in the brain stem and spinal cord be-
tween the IMPT0mm- and the IMPT5mm-plans compared
with the IMPT2mm-plan (Figure 3). Considering the ser-
ial organ with the highest D2% in each patient, either
the brainstem or the spinal cord, the D2%-difference to
the IMPT2mm-plan was significantly larger for the
IMPT0mm-plan compared with the IMPT5mm-plan (p =
0.016, F-test).
Discussion
Set-up margins alone cannot ensure dose coverage of
the CTV in IMPT-plans with multiple fields and high
in-field dose gradients [5,11]. Deviations in the position
of these dose gradients in the patient from spot to spot
due to set-up errors or range uncertainties can result in
Figure 2 Dose difference plots. Distribution of the dose difference obtained by subtracting the dose distribution of the IMPT2mm-plan from the
dose distributions of the IMPT0mm- and the IMPT5mm-plans. (a1) Dose difference IMPT0mm-IMPT2mm for patient 1. (a2) Dose difference IMPT5mm-
IMPT2mm for patient 1. The corresponding dose difference plots for patient 7 are shown in (b1) and (b2), respectively.
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optimization can lead to smooth dose gradients per field
across a target volume and can diminish the risk of pen-
cil beams stopping directly in front of an abutting nor-
mal tissue [5,8,9]. It makes use of the feature that set-up
errors in beam direction alone do not affect the distal
and proximal margin for that beam as also a beam-
specific PTV-margin concept would do [12] but unlikeFigure 3 Normal tissue exposure. Mean dose difference to the
ipsilateral temporal lobe and the cerebellum between the IMPT0mm-
and IMPT2mm-plans (red circles) and between the IMPT5mm- and
IMPT2mm-plans (green triangles) for the 7 patients (left vertical axis).
The respective differences in D2%, quantifying hot spots in the serial
organ of each patient exposed to the highest doses, i.e. the either
brain stem or the spinal cord, are also shown (right vertical axis).the PTV concept of expanding the CTV by set-up mar-
gin used in photon therapy. Scanned particle beams can
spare normal tissues in beam direction behind the target
volume and conform to the proximal contour of the tar-
get volume so that a reduction of normal tissue exposure
per beam can result. Unlike CTV expansion by set-up
margins, the robust IMPT optimization method also
considers the potential influence of lateral set-up errors
on the water equivalent depth of the distal and proximal
CTV border at a given lateral spot position due to lateral
density inhomogeneities in the entrance channel, e.g. if
bone is moved in front of the target volume at that spot
position due to set-up error. Multi-scenario based robust
IMPT-plans can maintain dose coverage of the target
volume better than PTV-based IMPT-plans [5,13]. On
the other hand, the spatial dose distribution can be con-
sidered as independent of small set-up errors and organ
motions for rotational or fixed-field intensity-modulated
photon therapy [14]. Thus, the PTV concept is usually
adopted to account for set-up errors in intensity-
modulated photon therapy. In this study, we showed
that for recurrent head and neck carcinomas robust
IMPT-plans perform the better relative to a photon
intensity-modulated plan the larger the set-up margin as
a part of the PTV is. This holds true for highly
constrained IMPT field arrangements with up to 7 fields.
Therefore, with increasing set-up margin portion of the
PTV due to larger set-up errors, robust optimization can
increase the on average lower conformity of IMPT in
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50% isodose found in the previous study [6] for 2 mm
set-up errors. Multiple scenarios, considered in robust
optimization could also by linked by elastic deformations
in the future to simulate internal motion and body de-
formation. The magnitude of range uncertainties as-
sumed might also vary slightly from institution to
institution [15].
Conclusion
Unlike the PTV-approach for photon IMRT, robust
multi-scenario based IMPT optimization can increas-
ingly reduce the normal tissue exposure around the tar-
get volume for recurrent head and neck cancer with
increasing set-up margin portion of the PTV.
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